<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01566123</url>
  </required_header>
  <id_info>
    <org_study_id>RETROWTS</org_study_id>
    <nct_id>NCT01566123</nct_id>
  </id_info>
  <brief_title>Trial of Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma (RETRO-WTS)</brief_title>
  <official_title>Clinical Phase I/II Trial to Investigate Preoperative Dose-Escalated Intensity-Modulated Radiation Therapy (IMRT) and Intraoperative Radiation Therapy (IORT) in Patients With Retroperitoneal Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Local control rates in patients with retroperitoneal soft tissue sarcoma (RSTS) remain&#xD;
      disappointing even after gross total resection, mainly because wide margins are not&#xD;
      achievable in the majority of patients. In contrast to extremity sarcoma, postoperative&#xD;
      radiation therapy (RT) has shown limited efficacy due to its limitations in achievable dose&#xD;
      and coverage. Although Intraoperative Radiation Therapy (IORT) has been introduced in some&#xD;
      centers to overcome these dose limitations and resulted in improved outcome, local failure&#xD;
      rates are still high even if considerable treatment related toxicity is accepted. As&#xD;
      postoperative administration of RT has some general disadvantages, neoadjuvant approaches&#xD;
      could offer benefits in terms of dose escalation, target coverage and reduction of toxicity,&#xD;
      especially if highly conformal techniques like intensity-modulated radiation therapy (IMRT)&#xD;
      are considered.&#xD;
&#xD;
      Therefore the RETROWTS trials has been designed as a prospective, one armed, single center&#xD;
      phase I/II study investigating a combination of neoadjuvant dose-escalated IMRT (50-56 Gy)&#xD;
      followed by surgery and IORT (10-12 Gy) in patients with at least marginally resectable RSTS.&#xD;
      The primary objective is the local control rate after five years. Secondary endpoints are&#xD;
      progression-free and overall survival, acute and late toxicity, surgical resectability and&#xD;
      patterns of failure. The aim of accrual is 37 patients in the per-protocol population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2007</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Control Rate</measure>
    <time_frame>5 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 5 years from first day of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to five years from first day of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>up to 3 months from first day of treatment</time_frame>
    <description>scored according to CTCAE 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Toxicity</measure>
    <time_frame>up to 5 years after first day of treatment</time_frame>
    <description>scored according to CTCAE 3.0 and RTOG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe acute gastrointestinal toxicity</measure>
    <time_frame>up to 3 months from first day of treatment</time_frame>
    <description>severe defined as grade &gt;= III, scored according to CTC AE 3.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Retroperitoneal Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Neoadjuvant intensity-modulated radiation therapy (IMRT)</intervention_name>
    <description>neoadjuvant intensity-modulated radiation therapy, single dose 2.0-2.4 Gy, total dose 50-56 Gy</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intraoperative radiation therapy (IORT)</intervention_name>
    <description>during surgery, 10-12 Gy (90% isodose) to the tumor bed or residual disease</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  histologically confirmed, primary or locally recurrent soft tissue sarcoma of the&#xD;
             retroperitoneal space&#xD;
&#xD;
          -  judged as at least marginally resectable&#xD;
&#xD;
          -  absence of distant metastases&#xD;
&#xD;
          -  tumor size ≥ 5 cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  missing written informed consent&#xD;
&#xD;
          -  missing histological confirmation of soft tissue sarcoma&#xD;
&#xD;
          -  Desmoid tumor (syn. aggressive fibromatosis)&#xD;
&#xD;
          -  judged as gross incomplete or not resectable&#xD;
&#xD;
          -  incomplete staging&#xD;
&#xD;
          -  presence of distant metastases&#xD;
&#xD;
          -  prior radiation therapy to the abdominal region&#xD;
&#xD;
          -  participation in another clinical interventional study&#xD;
&#xD;
          -  inflammatory bowel disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Debus, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 20, 2012</study_first_submitted>
  <study_first_submitted_qc>March 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2012</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Juergen Debus</investigator_full_name>
    <investigator_title>Prof. Dr. Dr.</investigator_title>
  </responsible_party>
  <keyword>retroperitoneal soft tissue sarcoma</keyword>
  <keyword>IMRT</keyword>
  <keyword>IORT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

